An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Trial Profile

An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs CPI 613 (Primary) ; Cytarabine; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 Results of interim analysis (n=30), presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Dec 2017 According to a Rafael Pharmaceuticals media release, new data from this trial will be presented at the 2017 American Society of Hematology Annual Meeting & Exposition.
    • 23 Mar 2017 According to a Cornerstone Pharmaceuticals media release, results from the trial could potentially lead to approval for treatment of a disease that historically has been extremely difficult to treat.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top